SPRO · Spero Therapeutics Inc
United States · RS rating 18 · As of 2026-11-03
| Price | 1.04 USD |
|---|---|
| 1-day change | +0.0% |
| RS rating (overall / 1M / 3M / 12M) | 18 / 34 / 34 / 18 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 31 / 4 / 53 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +507.7% |
| Sales growth Q/Q | +1201.1% |
| Distance from 52-week high | +65.1% |
| Market cap (USD) | $162.1M |